Table 3. Genes implicated in clinical trials involving MCL patients.

Genes implicated	Trial type, reference	Intervention/regimen	Findings	Cancer types, MCL (n)
ATM	Phase I[40]	Cyclophosphamide +Veliparib	Prolonged stable disease (>6 cyc.)	SLL (n = 2)
BCL-2	Phase I[72]	ABT-199	ORR 48%	NHL/MCL = 12
CCND1	Phase I[47]	Bortezomib+ Alvocidib	33% total response rate for NHL and progressive disease (PD) in MCL	NHL/MCL (n = 3)
CCND1	Phase I[49]	Flavopiridol	PR in MCL	NHL/MCL (n = 2)
CCND1	Phase II[50]	Flavopiridol	PR 3.3 months (n = 3); SD 3.4 months (n = 20); PD (n = 5). Overall response with no prior therapy is 11% vs. 6% with prior therapy	MCL (n = 28)
CCND1	Phase I[51]	Flavopiridol + Fludarabine + Rituximab	80% ORR for MCL (n = 10)	NHL/MCL/CLL
Epigenetic modifiers	Phase II[57]	Vorinistat + Rituximab	33% PR/ORR for MCL (M = 3)	NHL/MCL (n = 3)
Epigenetic modifiers	Phase II[55]	Vorinostat	ORR for MCL 0-60% (n = 4)	NHL/FL/MCL (n = 4)
Epigenetic modifiers	Phase I[58]	Panobinostat + Everolimus	100% PR for MCL (n = 3)	HL/NHL/MCL (n = 3)
Epigenetic modifiers	Phase II[56]	Vorinostat	OS 16.9 months for MCL (n = 9); SD 1/9	FL/MCL (n = 9)/MZL
Epigenetic modifiers	Phase I[54]	Vorinostat	SD (n = 1) & CRu (n = 1) for MCL	DLBCL/CTCL/MCL (n = 2)/FL
Epigenetic modifiers	Phase I[59]	Vorinostat + RICE	Sensitive 60% (n = 5) MCL	FL/MZL/DLBCL/MCL (n = 5)
Epigenetic modifiers	Phase I/II[61]	Abexinostat	ORR 27.3%; median PFS 3.9 months for MCL	FL/MCL (n = 11) (for phase II)

SLL=small lymphocytic lymphoma; NHL= non-Hodgkin's lymphoma; FL=follicular lymphoma; MCL= mantle cell lymphoma; MZL=marginal zone lymphoma; DLBCL= diffuse large B-cell lymphoma; CTCL= cutaneous T cell lymphoma